Bavarian Nordic A/S/DKr BAVA
07:00
09:00
11:00
12:55
14:55
1D1W1MYTD1Y5YMAX
About Bavarian Nordic A/S
Bavarian Nordic A/S is a biotechnology company based in Denmark, specializing in the development, manufacturing, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company’s core products include vaccines such as Jynneos/Imvanex/Imvamune for smallpox and monkeypox, as well as the Rabipur/RabAvert rabies vaccine. Established in 1994, Bavarian Nordic supports its global operations through its headquarters in Hellerup, Denmark, and production facilities in Kvistgaard. The company distinguishes itself through its proprietary MVA-BN technology platform, which enhances vaccine efficacy and safety, offering a strategic advantage in vaccine development and production.
Ticker
DKr BAVA
Sector
Primary listing
CSE
Employees
1,861
Headquarters
Hellerup, Denmark
Website
BAVA Metrics
BasicAdvanced
kr 14bn
11.93
kr 14.84
0.95
-
Price and volume
Market cap
kr 14bn
Beta
0.95
52-week high
kr 243.70
52-week low
kr 171.30
Average daily volume
194k
Financial strength
Current ratio
6.47
Quick ratio
3.5
Long term debt to equity
0.737
Total debt to equity
1.098
Interest coverage (TTM)
117.70%
Profitability
EBITDA (TTM)
1,399.497
Gross margin (TTM)
48.11%
Net profit margin (TTM)
19.71%
Operating margin (TTM)
12.91%
Effective tax rate (TTM)
26.41%
Revenue per employee (TTM)
kr 3,200,000
Management effectiveness
Return on assets (TTM)
3.48%
Return on equity (TTM)
9.68%
Valuation
Price to earnings (TTM)
11.931
Price to revenue (TTM)
2.347
Price to book
1.08
Price to tangible book (TTM)
2.01
Price to free cash flow (TTM)
10.693
Free cash flow yield (TTM)
9.35%
Free cash flow per share (TTM)
16.553
Growth
Revenue change (TTM)
-4.43%
Earnings per share change (TTM)
-10.71%
3-year revenue growth (CAGR)
13.41%
10-year revenue growth (CAGR)
22.10%
3-year earnings per share growth (CAGR)
52.14%
10-year earnings per share growth (CAGR)
13.69%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.